X

Trial Profile

A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Milnacipran (Primary)
Indications Fibromyalgia
Focus Registrational; Therapeutic Use
Sponsors Forest Laboratories

Most Recent Events

02 Sep 2010 Results regarding the impact of abrupt drug withdrawal were reported at the 13th World Congress on Pain.
02 Sep 2010 Results were reported at the 13th World Congress on Pain.
16 Jun 2010 Results pertaining to the impact of abrupt drug withdrawal have been presented at 11th Annual Congress of the European League Against Rheumatism (EULAR) 2010

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com